Publications Related to Our Trials and Research

This page lists some of our published papers. The names of the clinical trials associated with our papers are listed after each paper title.  For information on our previous trials, please visit our "Past Clinical Trials" page.


To find publications related to cancer research search PubMed.

  open book smaller view

  • Woodson, E. et al. Assessment of the Toxicities of Systemic Low-Dose Interleukin-2 Administered in Conjunction with a Melanoma Peptide Vaccine.  Journal of Immunotherapy. 2004; 27:380-388. (related to the Mel 36 trial). 
  • Chianese-Bullock, K. et al. Autoimmune Toxicities Associated with the Administration of AntitumorVaccines and Low-Dose Interleukin-2. Journal of Immunotherapy. 2005; 28:412-419. (related to trials Mel 31, 36, and 37).
  • Slingluff, C. et al. Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in
    Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or
    Pulsed on Dendritic Cells. Journal of Clinical Oncology. 2003; 21:4016-4026. (related to the Mel 31 trial).
  • Thompson, L. et al. Competition Among Peptides in Melanoma Vaccines for Binding to MHC Molecules. Journal of Immunotherapy. 2004; 27:425-431.
  • Evaluation of Peptide Vaccine Immunogenicity in Draining Lymph Nodes
    and Peripheral Blood of Melanoma Patients. International Journal of Cancer. 
    2001; 92:703-711. (related to the Mel 31 trial).
  • Yamshchikov, G. et al. Immunity to Melanoma Antigens: From Self-Tolerance to Immunotherapy. Advances in Immunology. 2006; 90. (related to all our melanoma trials). 
  • Slingluff, C. et al. Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting. Clinical Cancer Research. 2007; 13:21.  (related to the Mel 39 trial)
  • Slingluff, C. et al. Immunologic and Clinical Outcomes of Vaccination with a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule. Journal of Clinical Oncology. 2004; 22:4474-4485. (related to the Mel 36 trial).
  • Cragun, W. et al. Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients. Cancer Journal of Immunology and Immunotherapy. 2005; 54:1095-1105. (related to trials Mel 36 and Mel 39).
  • Chianese-Bullock, K. et al. MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma. The Journal of Immunology. 2005; 174:3080-3086. (related to the Mel 39 trial).
  • Slingluff, C. et al. Phase I Trial of a Melanoma Vaccine with gp100280-288 Peptide and Tetanus Helper Peptide in Adjuvant: Immunologic and Clinical Outcomes. Clinical Cancer Research. 2001; 7:3012-3024. (related to the Mel 16 trial). 
  • Yamshchikov, G. et al.Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma. Journal of Immunology. 2005; 174:6863-6871.